

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Pazopanib for the first line treatment of advanced and/or metastatic renal cell carcinoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equalities issues were raised during consultation on the draft scope, and therefore no changes were made to the draft scope.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

It was noted that the evidence for pazopanib was obtained from patients who have an ECOG performance status of 0 or 1 and therefore the recommendation reflects this. The Committee concluded that healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were raised. However, the Committee discussed the importance of considering pazopanib as an end of life treatment.
---

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
No	

5.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?
N/A	

6.	Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
N/A	

**Approved by Associate Director:** .....Frances Sutcliffe.....

**Date:** 16/02/2011

**Final appraisal determination**

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No	

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?
----	---

If so, what are the barriers to access for the specific group?
No

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
No

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
4.16 The Committee considered whether its recommendation was associated with any potential issues related to equality. The Committee concluded that healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.

**Approved by Programme Director:** Meindert Boysen

**Date:** 16/02/2011